English Summary
Beijing Xunyin Biotechnology Co., Ltd. is indexed in the China Little Giant company database. The Chinese legal name is 北京寻因生物科技有限公司. The profile is associated with Beijing. The report is grouped under Biomedicine. Recognition context: 2024 6th batch. Chinese source report date: 2026-06-12. 3 public evidence links are available on this page or in the Chinese report. The English brief covers company profile, product direction, industry-chain role, patent and R&D signals, scale indicators and policy-material checkpoints, with internal links to the company page, Chinese source report and related topic hubs.
Report Snapshot
| Company | Beijing Xunyin Biotechnology Co., Ltd. |
| Region | Beijing |
| Industry | Biomedicine |
| Published | 2026-06-12 |
| Chinese report | Open |
Company and Recognition Snapshot
Beijing Xunyin Biotechnology Co., Ltd. is indexed as a national-level Little Giant enterprise in Beijing. The English profile places the company under Biomedicine and records 2024 6th batch as the available recognition context.
| Recognition batch | 2024 6th batch |
| Region | Beijing |
| Industry | Biomedicine |
| Registered capital | RMB 13.16 million |
| Employee signal | 100-500 employees (SME reference) |
| Listed status | Not listed |
| Patent signal | 105 patent-related records |
| R&D signal | R&D investment detail not published in the English dataset |
Business and Industry-chain Position
Chinese public records indicate software, systems and digital-technology activity, medical-device or biomedicine activity, R&D, design and engineering activity. The recorded industry-chain position is Biomedicine and medical devices / Recorded position. This places the company in a policy-relevant segment for peer comparison by region, industry and batch.
Technology, Patent and R&D Signals
The public profile records 105 patent-related records. The R&D signal is: R&D investment detail not published in the English dataset. Patent and R&D information should be read with product direction, customer evidence and chain position rather than as isolated threshold items.
Policy-material Review Points
- Verify whether the company's main business, niche market and product evidence all point to Biomedicine.
- Check that patent, R&D, employee and financial fields support the same core product direction.
- Compare the company with peers in the same province, industry and recognition batch before using the profile for supplier screening or policy research.
- Use the linked Chinese source report for original-language evidence and source links.
Original Report and Profile
For the underlying database record, open the English company profile. For full-length analysis, original-language wording and public evidence links, open the Chinese source report.